TCT-741 Cost-Effectiveness of Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk: Initial Results Based on 1-Year Outcomes From the Evolut Low Risk Trial

Transcatheter aortic valve replacement (TAVR) in patients at low surgical risk has been shown to be superior compared with surgical aortic valve replacement (SAVR) with regard to a composite of death, stroke, or rehospitalization at 1 year and noninferior with regard to a composite of death or